Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-08-09 | 2024-06 | -0.31 | -0.37 | -0.06 | -19.35% |
2024-05-30 | 2024-03 | -0.33 | -0.28 | 0.05 | 15.15% |
2024-02-09 | 2023-12 | -0.45 | -1.79 | -1.34 | -297.78% |
2023-11-09 | 2023-09 | -1.2 | -1.8 | -0.6 | -50.00% |
2023-08-09 | 2023-06 | -1 | -0.4 | 0.6 | 60.00% |
2023-06-22 | 2023-03 | -1.2 | -2.3 | -1.1 | -91.67% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-14 | B of A Securities | Upgrade | Underperform | Underperform |
2023-06-11 | CIBC | Upgrade | Underperformer | |
2023-05-01 | Piper Sandler | Upgrade | Underweight | |
2023-02-16 | Cantor Fitzgerald | Upgrade | Neutral | |
2022-11-06 | Cantor Fitzgerald | Upgrade | Neutral | |
2022-11-01 | Bernstein | Upgrade | Underperform |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2022-07-31 | Gedeon (Christelle) | Senior Officer of Issuer | 0.00 | Opening Balance-Initial SEDI Report |
2022-06-28 | Greenstar Canada Investment, L.P. | 10% Security Holder of Issuer | 67.00M | Redemption, retraction, cancelation, repurchase |
2022-06-08 | Hong (Judy Eun Joo) | Senior Officer of Issuer | 2.67K | Exercise of rights |
2022-05-30 | Klein (David Eric) | Director or Senior Officer of 10% Security Holder | 242.01K | Exercise of rights |
2022-09-29 | Lazzarato (David Angelo) | Director of Issuer | 15.11K | Exercise of rights |
2022-09-29 | Schmeling (Judy A) | Director of Issuer | 41.29K | Exercise of rights |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Luxor Capital Group, LP | 16.55M | 6.42M | 2.26% |
2023-06-29 | Vanguard Group Inc | 10.97M | 4.26M | 1.50% |
2023-03-30 | ETF Managers Group, LLC | 8.11M | 14.19M | 1.11% |
2023-06-29 | Two Sigma Investments, LP | 7.94M | 3.08M | 1.08% |
2023-06-29 | Verition Fund Management, LLC | 6.26M | 2.43M | 0.85% |
2023-06-29 | Mirae Asset Global Investments Co., Ltd. | 4.83M | 1.87M | 0.66% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | ETF Managers Tr-EFTMG Alternative Harvest ETF | 11.00M | 4.27M | 1.50% |
2023-09-29 | Global X Fds-The Global X Cannabis ETF | 3.54M | 2.77M | 0.48% |
2023-06-29 | Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund | 2.75M | 1.07M | 0.38% |
2023-07-30 | Vanguard International Stock Index-Total Intl Stock Indx | 2.14M | 1.06M | 0.29% |
2023-07-30 | Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index | 635.59K | 313.34K | 0.09% |
2023-05-30 | Schwab Strategic Tr-Schwab International Small Cap Equity ETF | 567.69K | 474.02K | 0.08% |
Split | Date |
---|---|
1 : 10 | 2023-12-20 |
-
$CGC $WEED.TO. The reason it was at $45 to $1 is because people bought into the stock too much leading up to Canadian legalization… it crashed when it was overvalued… over the years the company got ambitious and spent too much trying to prepare for American legalization. Because that never happened, the company was sitting on tons of assets but unable to sell within the United States. They were over prepared for a market they had no access to. With the company settling many debts and law changing around the corner the rumor is the company is positioned well for the United States once legalized. The company is already making massive profits monthly in canada - just earning have been offset by spending/debt for the past few years
-
-
bears are changing their tune… $CGC will prevail
-
Buying more… needs to pass $1 and hold past for 10 days… getting close and News around the corner for descheduling $CGC… don’t let them get your shares
-
I bought that dip $CGC … think beyond the day people
-
Sold at .83, back in at .73 $CGC. Read the charts
-
"During this quarter, we executed an agreement with United States Air Force Academy ("USAFA") for an initial amount of US$7.3million in funding from the Defense Threat Reduction Agency and USAFA for our ATI-1701 vaccine, a crucial defense against Tularemia, which is a top-priority biothreat. Our partnership with USAFA and the recent agreement execution will enable us to advance this program towards an Investigational New Drug ("IND")," said Don Cilla, Pharm.D., M.B.A., President and Chief Executive Officer of Appili Therapeutics. "Additionally, securing US patent coverage through at least 2039 for ATI-1501, our Metronidazole formulation, is a significant milestone leading up to the anticipated FDA Prescription Drug User Fee ("PDUFA") date on September 23, 2023. We look forward to receiving milestone payments and royalties from our partner, Saptalis Pharmaceuticals LLC ("Saptalis"), in the coming quarters based on their submission and commercialization plans. These achievements are expected to position us with the required resources to continue to make progress in advancing our infectious disease assets."
-
Don’t buy calls… buy stocks… buy heavy on any dips… push this pig past .70 today $CGC
-
Don’t puss out… buy $CGC… so much upside still
-
$CGC is holding strong against its competitors today… heading for $1 this week
-
Keep pushing… needs to break .68 $CGC
-
Add on this dip here $CGC
-
Closing at .68 CGC
-
-
Strong insider buying on august 22… something is brewing for sure $CGC
-
News tomorrow… big boys coming in… this is ripping for real $CGC
-
Bears about to shit $CGC
-
Buy here bull flag is primed $CGC
-
Buy shares not calls… will blow past $1 tomorrow $CGC
-
Cannabis Stocks Get Boost as Trump Backs Easing Restrictions
investopedia.com • -
Best Canadian Cannabis Stocks to Watch in September
marijuanastocks.com • -
Must-buy stocks if Kamala Harris wins the U.S. election
finbold.com • -
3 Weed Stocks Sinking on Reclassification Hearing Update
schaeffersresearch.com • -
Top Canadian Cannabis Stocks to Watch Now: High-Growth Opportunities in 2024
marijuanastocks.com • -
3 Of Today's Top Canadian Marijuana Stock Picks For Investors
marijuanastocks.com • -
Canopy Growth CEO to step down
reuters.com • -
Canopy Growth Announces CEO Succession Plan
prnewswire.com • -
Canopy Growth Stock: Can It Sustain Recent Gains?
marketbeat.com •